ABCL vs HCA · rev $28.8M vs P/E 17, rev $75.60B
Abcellera Biologics Inc (ABCL) versus HCA Holdings Inc (HCA) — a side-by-side from cached financials, not a winner call.
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
HCA Holdings Inc (HCA) is a medical care facilities company listed on US.
Latest reported ABCL revenue for 2024-12-31 was $28.8M. Net income was -$162.9M. Revenue was down 24.2% from 2023-12-31 to 2024-12-31. ABCL currently screens at market cap $1.12B.
Latest reported HCA revenue for 2025-12-31 was $75.60B. Net income was $6.78B. Revenue was up 7.1% from 2024-12-31 to 2025-12-31. HCA currently screens at market cap $91.01B and trailing P/E 16.8.
ABCL currently screens at market cap $1.12B. HCA currently screens at market cap $91.01B and trailing P/E 16.8.
Not investment advice. Open the ABCL and HCA stock pages for the full models.
Not investment advice.